VENCLEXTA  + azacitidine or decitabine (VEN + AZA or DEC)

VENCLEXTA + low-dose cytarabine (VEN + LDAC)

Tumor Lysis Syndrome (TLS)

  • TLS is an important risk when initiating treatment in patients with AML
  • VEN + AZA or DEC: in clinical trials, no reported events of laboratory or clinical TLS with implementation of dosing ramp-up plus standard TLS prophylaxis and monitoring 1
  • VEN + LDAC: in clinical trials, the incidence of TLS was 3% (2/61) with implementation of dose ramp-up in addition to standard prophylaxis and monitoring measures. All events were laboratory TLS, and all patients were able to reach the target dose 1

AML=acute myeloid leukemia.
Adverse reactions graded using NCI Common Terminology Criteria for Adverse Events version 4.0.
*Includes multiple adverse reaction terms.